TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8164028
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate (1.8, 2.4, 3.0, and 5.0 mg/kg) administered intravenously over 20 minutes, starting 30 minutes before chemotherapy.
Study: 8164028
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate (doses > 2.4 mg/kg)
Study: 1920009
Drug: Routine maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine maintenance therapy (RMT)
Study: 582685
Drug: L-tryptophane plus
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophane plus oxprenolol
Study: 20478383
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg/day for 12 weeks
Study: 31519283
Drug: Starch placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch placebo 500 mg/day for 12 weeks
Study: 28095099
Drug: Exercise-nutritional supplement
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-nutritional supplement program (ENP)
Study: 17917321
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg plus Hydrochlorothiazide 12.5 mg
Study: 17917321
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg plus Hydrochlorothiazide 6.25 mg
Study: 17917321
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg plus Hydrochlorothiazide 6.25 mg
Study: 15536109
Drug: Carvedilol (6.25-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (6.25-25 mg, twice daily)
Study: 15536109
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (50-200 mg, twice daily)
Study: 21166828
Drug: Emdogain Gel
Normalized name: Memogain
DrugBank: Benzgalantamine (DB19353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emdogain Gel (Biora AB, Malmö, Sweden)
Study: 7934491
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg cA2
Study: 7934491
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg cA2
Study: 2904392
Drug: sulphasalazine 2
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulphasalazine 2 g/day
Study: 21729166
Drug: 311 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 311 nm UVB therapy
Study: 10903487
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice daily
Study: 9018514
Drug: Topical upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical upper airway anesthesia with 0.2% tetracaine
Study: 29864430
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine hydrochloride (1.44 g/day) combined with hyaluronate sodium injections
Study: 29864430
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo combined with hyaluronate sodium injections
Study: 23763270
Drug: Topical nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nicotinamide (NCT) 4% cream
Study: 19828470
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg, n = 5)
Study: 19828470
Drug: Mepolizumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (1500 mg, n = 5)
Study: 12143913
Drug: Paroxetine controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled-release (CR) 25-62.5 mg/day
Study: 12143913
Drug: Paroxetine immediate-release
Normalized name: paroxetine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine immediate-release (IR) 20-50 mg/day
Study: 9868616
Drug: Silver preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver preparations in burns
Study: 1832454
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg naproxen b.i.d. for 3 months
Study: 30716790
Drug: Early Calsurf
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Calsurf administration (n=154)
Study: 30716790
Drug: Rescue Calsurf
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue Calsurf administration (n=151)
Study: 27679519
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with losartan
Study: 6160345
Drug: Low-dose furosemide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide (40 mg/day)
Study: 6160345
Drug: Normal controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal controls (no therapy)
Study: 31116151
Drug: Doxazosin mesylate
Normalized name: Doxazosin Mesylate
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin mesylate GITS (4 mg/day)
Study: 31116151
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 mg/day)
Study: 25928214
Drug: DrotAA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DrotAA + steroids
Study: 25928214
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + steroids
Study: 17207038
Drug: Hypothetical preventer
Normalized name: Preventeza
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hypothetical preventer medication
Study: 17207038
Drug: Current inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current inhaled corticosteroid medication
Study: 17207038
Drug: No asthma
Approvals — FDA: no, EMA: no, PMDA: no
Description: No asthma medication
Study: 15146933
Drug: Epinastine hydrochloride
Normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine hydrochloride (20 mg/day, once daily)
Study: 28042082
Drug: Chard gel
Normalized name: SWISS CHARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chard gel (GEL)
Study: 24053706
Drug: SLIT (sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT (sublingual immunotherapy)
Study: 24053706
Drug: SCIT (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIT (subcutaneous immunotherapy)
Study: 21703676
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment with subcutaneous enoxaparin (≥5 days) followed by oral anticoagulation (≥90 days)
Study: 21703676
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment with subcutaneous enoxaparin (≥5 days) followed by oral anticoagulation (≥90 days)
Study: 19231298
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (24 sessions over 3 months)
Study: 15142202
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg am and 30 mg pm for 7 days
Study: 11114574
Drug: L-carnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (500 mg/day) for 3 months
Study: 9496487
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral desensitization program
Study: 7766945
Drug: Phenylalanine-restricted diet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine-restricted diet, maintaining maternal blood phenylalanine levels between 120 and 360 mumol/l before conception and during pregnancy.
Study: 31537420
Drug: suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1 mg/kg
Study: 11521932
Drug: Low-energy shock-wave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy shock-wave therapy (ESWT), 6,000 impulses (energy flux density, 0.11 mJ/mm2) in three sessions after local anaesthesia
Study: 3946248
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 to 300 mg/day)
Study: 3946248
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 to 15 mg/day)
Study: 24452085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with graduated middle stretch compression bandage and low dose unfractionated heparin (LDUH) injections
Study: 20044067
Drug: Electronic prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic prescription for calcium carbonate with vitamin D supplement
Study: 19080566
Drug: AutoCPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AutoCPAP treatment for 1 month
Study: 19080566
Drug: ASV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASV treatment for 1 week
Study: 16719171
Drug: Ifosphamide (IF)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosphamide (IF) treatment in doses from 1.5 g/m2 to 3 g/m2 for 3 to 5 days.
Study: 12869359
Drug: Oxygen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (3 L/minute)
Study: 12869359
Drug: Air (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (3 L/minute)
Study: 10868714
Drug: Pressurized metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized metered dose inhaler (pMDI)
Study: 2067212
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody (mAb) against human IL-6
Study: 6437128
Drug: Danazol 400
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 400 mg
Study: 6437128
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg
Study: 6437128
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg
Study: 30040706
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound therapy in addition to hotpack, TENS, and exercise
Study: 20630656
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of morphine with an NMDA‐receptor antagonist
Study: 12518850
Drug: Sulfadoxine‐pyrimethamine (SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (SP) treatment
Study: 9706827
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered in prehospital setting (Gr.1)
Study: 9706827
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered in hospital setting (Gr.2)
Study: 2653174
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg per os)
Study: 9291
Drug: Chlorthalidone 100
Normalized name: chlorthalidone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 100 mg/day
Study: 9291
Drug: Chlorthalidone 200
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 200 mg/day
Study: 29798418
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL‐11 treatment
Study: 23118268
Drug: 10-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV)
Study: 23118268
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vCRM)
Study: 7936516
Drug: 2-mg intravaginal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-mg intravaginal prostaglandin E2 (PGE2) suppositories
Study: 3585441
Drug: Adr 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr 70 mg/m2 IV day 1 and every 3 weeks
Study: 3585441
Drug: Adr 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr 20 mg/m2 IV day 1, 2, and 3, and 15 mg/m2 IV day 8 and weekly thereafter
Study: 3585441
Drug: Adr 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adr 60 mg/m2 IV day 1 and DTIC 250 mg/m2 days 1 to 5, repeated every 3 weeks
Study: 3585441
Drug: Adr weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adr weekly
Study: 28625402
Drug: Drug eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug eluting stent (DES group)
Study: 21968667
Drug: 3% oregano
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% oregano extract ointment
Study: 16817643
Drug: Daily activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activities (sitting, walking, running, jumping)
Study: 12838499
Drug: Tacrolimus in
Normalized name: tacrolimus Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus in combination with MMF
Study: 12838499
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy with MMF
Study: 9363861
Drug: Intensive-course 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intensive-course 5-FU plus l-leucovorin with I.V. leucovorin (100 mg/m2)
Study: 9363861
Drug: Intensive-course 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intensive-course 5-FU plus oral (d,l)-leucovorin (125 mg/m2)
Study: 9363861
Drug: Intensive-course 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intensive-course 5-FU plus I.V. (d,l)-leucovorin (200 mg/m2)
Study: 8239918
Drug: Vratizolin (3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vratizolin (3% hydrophilic cream or ointment, four times daily)
Study: 8239918
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (zinc ointment, Aphtin, Oxycort, Dicortinef)
Study: 3699121
Drug: Fenoterol powder
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol powder inhaler with fast inhalation (16-19 l/min)
Study: 24725808
Drug: Stiripentol 500
Normalized name: stiripentol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stiripentol 500 mg
Study: 24725808
Drug: Stiripentol 1000
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stiripentol 1000 mg
Study: 24725808
Drug: Stiripentol 2000
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stiripentol 2000 mg
Study: 24725808
Drug: Stiripentol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stiripentol (all doses)
Study: 20834165
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum No. 14 (LP14) at a dosage of 8.7×10(8)
Study: 17689732
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.i.d.)
Study: 15842286
Drug: PgE(2) 1
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PgE(2) 1 mg
Study: 15842286
Drug: PgE(2) 2
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PgE(2) 2 mg
Study: 11831913
Drug: 2'7'‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein, acetoxymethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2'7'‐bis‐(2‐carboxyethyl)‐5‐(and‐6)‐carboxyfluorescein, acetoxymethyl ester (80 microg) applied via subconjunctival injection 15 minutes prior to trabeculectomy, followed by intraoperative illumination with diffuse blue light (450‐490 nm) for 8 minutes
Study: 8613282
Drug: Metronidazole 7.5
Normalized name: metronidazole 7.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 7.5 mg/kg thrice daily for 5 days
Study: 2125241
Drug: Gallopamil infusion
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil infusion (0.03 mg/kg bolus followed by continuous infusion at 0.02 mg/kg/h for the first 24 hours and 0.03 mg/kg/h for the last 48 hours)
Study: 2125241
Drug: Gallopamil infusion
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil infusion
Study: 161694
Drug: Plasmin inhibitors
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmin inhibitors measured with a functional assay
Study: 30284385
Drug: Topical cyclosporine-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine-A 2% eye drops
Study: 26530718
Drug: JinQi Jiangtang
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JinQi Jiangtang tablets
Study: 21070228
Drug: Topiramate plus
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate plus placebo injections
Study: 21070228
Drug: OnabotulinumtoxinA injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA injections plus placebo tablets
Study: 19577745
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution lavage
Study: 8810653
Drug: Cadralazine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (single oral dose)
Study: 3868306
Drug: Rectally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectally administered diazepam (0.6 mg/kg)
Study: 31258108
Drug: Sucralose (780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (780 mg/d for 7 days)
Study: 25311296
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (including selective estrogen receptor modulators, selective estrogen receptor downregulators, and aromatase inhibitors)
Study: 8945073
Drug: Propafenone (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (450 or 600 mg)
Study: 8945073
Drug: Digoxin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (1 mg) or Placebo
Study: 1769127
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 2 IU/m2 subcutaneously daily for 4 months
Study: 26613620
Drug: Daily meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily meal delivery
Study: 26613620
Drug: Once-weekly meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly meal delivery
Study: 12733709
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Study: 10227010
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 hormone replacement therapy
Study: 8755201
Drug: 0.4 mg/ml
Normalized name: thymol 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/ml mitomycin C
Study: 8755201
Drug: 0.2 mg/ml
Normalized name: iodine 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/ml mitomycin C
Study: 8755201
Drug: 0.1 mg/ml
Normalized name: deanol 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/ml mitomycin C
Study: 1848996
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (control) - standard alternating chemotherapy regimen
Study: 1848996
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (investigative) - simultaneous administration of cyclophosphamide + lomustine alternating with cyclophosphamide + doxorubicin, and doxorubicin + lomustine
Study: 7075640
Drug: Labetalol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100 mg tid)
Study: 7075640
Drug: Clonidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.1 mg tid)
Study: 30539384
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg/day for 6 months
Study: 30539384
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban for 6 months (Control)
Study: 28371242
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN-OT) for 5 days
Study: 28371242
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo spray for 5 days
Study: 26015309
Drug: Cyclic 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic 15 mg MPA
Study: 26015309
Drug: Continuous 15
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 15 mg MPA
Study: 19657698
Drug: Exponential decrease
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exponential decrease group (group 1) vs. Nearly exponential decrease group (group 2) and Randomized clearance group (group 3) in stage II rectal cancer
Study: 9657561
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 336 microg x day(‐1)
Study: 8593713
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg daily) for 6 weeks
Study: 8593713
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg daily) for 12 weeks